Among them, glucagon-like peptide-1 (GLP-1), secreted from intestinal L-cells in response to nutrient ingestion, has attracted much attention because of its mimetics for the treatment of obesity (69), lowering glucose levels, and improving insulin sensitivity in individuals with type 2 diabetes and in animal models (70). This evidence concerns the gene GCG and type 2 diabetes mellitus.